According to our new research study on “Medical Enzyme Technology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Enzyme Type and Application,” the market is expected to reach US$ 6,700.00 million by 2028 from US$ 4,012.57 million in 2020; it is estimated to grow at a CAGR of 6.7% from 2021 to 2028.

Enzymes play a crucial role in the metabolic activities of all organisms, whether animal, human, plant, or microbial. They have an extensive range of applications in microbial biotechnology and diagnosis processes. The abnormality of the enzyme metabolism system leads to many metabolic diseases. Studies have shown that many diseases are related to the components of the enzyme metabolism system and have been widely used in the clinical examination as a specific disease marker. Further, enzymes can be used as medicines to treat a range of diseases; they are called medicinal enzymes.

For example, trypsin can be used not only to accelerate wound healing and dissolve blood clots but also to remove necrotic tissue and inhibit the proliferation of contaminating microorganisms. L-asparaginase can be used to treat cancer by depriving nutrients needed by the growth of cancer cells. Protease (like multi-enzyme tablets) can be used to treat dyspepsia, and it has an anti-inflammatory effect. Moreover, lipase, superoxide dismutase, nattokinase, soybean meal plasmin, and thrombin, among others, can be used to treat diseases.

Download Sample PDF Copy @ https://bit.ly/3ydIbEC

Based on enzyme type, the medical enzyme technology market is segmented into digestive enzymes, thrombolytic enzymes, hydrolases, and endonucleases. The hydrolases segment held the largest share of the market in 2020; however, the thrombolytic enzymes segment is anticipated to register the highest CAGR of 7.2% in the market during the forecast period.

The medical enzyme technology market majorly consists of companies such as Merck; Thermo Fisher Scientific Inc.; Novozymes; TAKEDA PHARMACEUTICAL COMPANY LIMITED; Agilent Technologies; Inc.; Danaher (Cytiva); Sanofi; Asahi Kasei Corporation; Promega Corporation; Amano Enzyme Inc; and Genzyme Corporation. The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio. For instance, in March 2021, Amano Enzyme Inc. introduced Umamizyme Pulse, a non-GMO enzyme engineered for use in a variety of plant protein products to produce a good, savory (umami) flavor similar to that produced by monosodium glutamate (MSG); the products also provide the feel of richness and complexity (kokumi).

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1–646–491–9876